Format

Send to

Choose Destination
Urology. 2018 Apr 13. pii: S0090-4295(18)30315-7. doi: 10.1016/j.urology.2018.04.001. [Epub ahead of print]

Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.

Author information

1
Consortium on Disparities in Urologic Conditions, Charlotte, NC. Electronic address: robmarw@prodigy.net.
2
Ghent University, Maastricht, Netherlands. Electronic address: leandervanneste@gmail.com.
3
Vanderbilt University, Nashville, TN. Electronic address: kelvin.a.moses@vanderbilt.edu.
4
Advanced Urology Centers of New York, New York, NY. Electronic address: Cbarnswell@imppllc.com.
5
Tulane University, New Orleans, LA. Electronic address: jsilbers@tulane.edu.
6
Associated Urologists of North Carolina, Raleigh, NC. Electronic address: mjalkut@gmail.com.
7
Chesapeake Urology, Baltimore, MD. Electronic address: rtutrone@cua.md.
8
Associated Urological Specialists, Orland Park, IL. Electronic address: J.Sylora@auspecialists.com.
9
Georgia Urology, Duluth, GA. Electronic address: Ranglade@gaurology.com.
10
MidAtlantic Urology Associates, Greenbelt, MI. Electronic address: fin0025murdock@yahoo.com.
11
Houston Metro Urology, Houston, TX. Electronic address: zvis45@hotmail.com.
12
Palmetto Urology, Orangeburg, SC. Electronic address: Toddvb@yahoo.com.
13
Piedmont Physicians Group, Atlanta, GA. Electronic address: nikhil.shah@piedmont.org.
14
MDxHealth, Irvine, CA. Electronic address: michael.carter@mdxhealth.com.
15
MDxHealth, Irvine, CA. Electronic address: manuel.krispin@mdxhealth.com.
16
MDxHealth, Irvine, CA. Electronic address: jack.groskopf@mdxhealth.com.
17
Ghent University, Ghent, Belgium. Electronic address: wim.vancriekinge@gmail.com.

Abstract

OBJECTIVES:

To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations.

METHODS:

The study population consisted of 211 AA men from seven urology centers across the U.S., all of whom were undergoing 12-core trans-rectal ultrasound guided repeat biopsy within 30 months from a negative index biopsy. All biopsy cores from the negative index biopsy were profiled for the epigenetic biomarkers GSTP1, APC and RASSF1 using ConfirmMDx for Prostate Cancer.

RESULTS:

Upon repeat biopsy, 130/211 (62%) subjects had no prostate cancer (PCa) detected and 81/211 (38%) were diagnosed with PCa. Of the subjects with PCa, 54/81 (67%) were diagnosed with Gleason Score (GS) ≤ 6 PCa and 27/81 (33%) with GS ≥7 disease. For detection of PCa at repeat biopsy, ConfirmMDx sensitivity was 74.1% and specificity 60.0%, equivalent to prior studies (P=0.235 and 0.697, respectively). For detection of GS ≥ 7 PCa, sensitivity was 78% and specificity 53%. The negative predictive values for detection of all PCa and GS ≥ 7 PCa were 78.8% and 94.2%, respectively.

CONCLUSIONS:

In this group of AA men, we successfully validated an epigenetic assay to assess the need for repeat biopsy. Results were consistent with previous studies from predominantly Caucasian populations. Therefore, the ConfirmMDx assay is a useful tool for risk stratification of AA men who had an initial negative biopsy.

KEYWORDS:

African American; epigenetic; methylation; prostate biopsy; prostate cancer

PMID:
29660369
DOI:
10.1016/j.urology.2018.04.001
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center